Announcing Earth Day Plus (Apr 22 to May 3) – VC-Founder Matchup + Live Sessions. Learn More

Diadem Biotherapeutics

Engineering the next class of biologics to treat chronic inflammatory diseases

Team

Woytek Bartkowski

CTO & Co-Founder

Mickey Pentecost

CEO & Co-Founder

Company details

Diadem Biotherapeutics, Inc. is a platform therapeutics company developing a broad pipeline of first-in-class immunotherapies. Diadem is engineering exosomes to be inhalable cell-specific immune modulators. Exosomes are small, virus-sized particles released by cells to communicate throughout the body.

Leveraging expertise in genetic engineering and scalable bioprocessing, Diadem is developing cell secreted nanovesicles precisely engineered to deliver signals that mimic natural cell-to-cell signaling. Diadem’s unique approach enables precise modulation of targets that play a role in chronic inflammation, autoimmune diseases and immune control of cancers, addressing some critical unmet clinical needs. For more information, visit www.diadembio.com.

Get In Touch with Diadem Biotherapeutics

Please tell us a little bit about yourself and why you'd like to get connected. Diadem Biotherapeutics + SOSV will follow up with you via email.

Hidden
Hidden
Hidden
Hidden

No Offer, Solicitation, Advice, or Recommendation

Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.